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Background: Adipose tissue (AT) contributes to metabolic dysfunction through imbalanced production of
adipokines, including cytokines. Visceral AT in particular is associated with metabolic disorders, indicating a specific
secretory status. The relative significance of different human AT depots in adipokine release is not fully known.
Further, previous in vitro systems usually included medium containing bovine serum albumin (BSA), which may
induce cytokine release. Our aim was to compare release of a number of adipokines/cytokines – all implicated in
insulin resistance – from human subcutaneous and visceral AT in a short-term incubation system minimizing
cytokine induction and including repeated measurements during 24 h. A prerequisite was to evaluate a potential
alternative to BSA in the incubation medium.
Methods: Subcutaneous and/or visceral AT from 17 patients (age 20–68 years; BMI 22.6–56.7 kg/m2) undergoing
elective surgery was incubated for 2, 4, 6, 8, and 24 h in medium with or without 1% BSA or human serum albumin
(HSA). Medium concentrations of adiponectin, chemerin, nine cytokines, dipeptidyl peptidase 4 (DPP4), and
omentin were analyzed by multiplex immunoassay or ELISA. Adipocyte size, AT macrophage density, and medium
concentrations of endotoxin were determined.
Results: Cytokine release was induced by BSA but not by HSA. In evaluation of the final incubation protocol
including 1% HSA, and as expected, adiponectin release was higher from subcutaneous biopsies of nonobese than
of obese subjects and inversely associated with adipocyte size; omentin was released almost exclusively from
visceral AT. Exploratory incubations revealed more abundant release of chemerin, cytokines (except IL-6), and DPP4
from the visceral depot, while adiponectin release was higher from subcutaneous than visceral AT. Release was
linear for a maximum of 2–6 h. Macrophage density was higher in visceral than subcutaneous AT. Levels of
endotoxin in the medium were negligible.
Conclusions: Adiponectin, chemerin, many cytokines, and DPP4 are released from human AT in a depot-
dependent manner. These results highlight functional differences between visceral and subcutaneous AT, and a
mechanistic link between regional fat accumulation and metabolic disorders. Supplementation of human AT
incubation medium with HSA rather than BSA is recommended to minimize induction of cytokine release.
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Adipose tissue is a major signaling organ that produces
and releases many proteins with autocrine, paracrine, and
endocrine activity, the so-called adipokines [1,2]. Dysregu-
lated secretion of adipokines, caused by obesity and/or
adipose tissue dysfunction, may contribute to the patho-
genesis of metabolic disease, such as insulin resistance,
type 2 diabetes, and cardiovascular disease [3]. Much at-
tention has focused on adipokines with pro-inflammatory
or anti-inflammatory activities since there is evidence of a
connection between obesity, its co-morbidities, and signs
of chronic low-grade inflammation [4,5].
Accumulation of visceral fat in particular is strongly
associated with metabolic disorders [6,7], indicating that
this depot may have a specific secretory status. Differ-
ences in cellular composition, adipocyte size, or other in-
trinsic factors could account for the regional specificity
in adipokine release [8,9]. However, the relative signifi-
cance of human subcutaneous and visceral adipose tis-
sue in adipokine release has not been fully elucidated.
Interestingly, gene expression studies revealed that ex-
pression of molecules involved in inflammation is higher
in visceral adipose tissue [10-12]. However, differences
in specific mRNA expression levels may not always be
reflected in corresponding differences at the level of pro-
tein release. Short-term incubation of tissue pieces and
subsequent analysis of the medium has been used to de-
termine which proteins are actually released from adi-
pose tissue depots and to what extent. Various systems
for this purpose have been described that differ in sup-
plementation of the medium, incubation time, propor-
tion of tissue to medium, and other factors that may
affect the outcome [13-17]. Thus, the challenge using an
incubation strategy is to obtain results that reflect the
in vivo situation [18].
Addition of bovine serum albumin (BSA) to the medium
is often recommended in protocols for adipose tissue in-
cubation, since albumin binds fatty acids that are mobi-
lized and exert toxic effects when unbound [19]. In 2006
it was reported that BSA markedly induces production
and release of cytokines from isolated human adipocytes
[20]. This suggests that a BSA alternative not inducing
cytokine release would be optimal, for example when
comparing adipokine/cytokine release from specific adi-
pose tissue depots [18]. Human serum albumin (HSA) has
previously been used for supplementation of medium for
both short-term and long-term incubation of human adi-
pose tissue [16,21]. However, the influence of BSA versus
HSA on cytokine release from human adipose tissue
in vitro has not been assessed.
In this study, our aim was to compare the release of
adipokines, including cytokines and other inflammatory/
metabolic biomarkers, from human subcutaneous and
visceral adipose tissue in a short-term incubation systemminimizing induction of cytokine release, and including
repeated measurements during 24 h. Further, a pre-
requisite was to first evaluate the influence of different
albumin preparations regarding induction of cytokine re-
lease from human AT. Using our final incubation proto-
col, we investigated nine pro-inflammatory cytokines,
the anti-inflammatory and intensively studied adiponec-
tin, and chemerin and dipeptidyl peptidase 4 (DPP4), all




Adipose tissue biopsies were obtained from 17 patients
(6 men and 11 women) undergoing elective abdominal
surgery (abdominoplasty in 5, gall bladder removal in 2,
hysterectomy in 1, and Roux-en-Y gastric bypass (RYGB)
in 9). The mean age was 48.7 ± 13.1 yr (range 20–68 yr),
and the mean BMI was 35.8 ± 10.8 kg/m2 (range 22.6–
56.7 kg/m2). Subcutaneous abdominal adipose tissue bi-
opsies were obtained from all subjects. Paired biopsies of
subcutaneous and visceral (omentum) adipose tissue were
collected from the 11 subjects (5 men and 6 women)
undergoing gall bladder surgery or RYGB; these subjects
had a mean age of 52.2 ± 15.1 yr (range 20–68 yr) and a
mean BMI of 41.6 ± 8.9 kg/m2 (range 27.0–56.7 kg/m2).
No subjects with malignant disease were included. All par-
ticipants gave oral and written consent. The study was
conducted in accordance with the Declaration of Helsinki
and approved by the Regional Ethical Review Board,
University of Gothenburg.
Short-term incubation
Biopsies were initially handled as described in our proto-
col for long-term incubation [21,22]. In brief, pieces of
adipose tissue (5–15 mg) were prepared under sterile
conditions and incubated in plastic tubes (250 mg of tis-
sue/10 mL of medium). In our final short-term incuba-
tion protocol, the tissue explants were incubated for 2,
4, 6, 8, and 24 h (one incubation tube for each incuba-
tion period) in Medium 199 (Invitrogen, Carlsbad, CA)
supplemented with 30 mM NaHCO3, 0.15 μM adeno-
sine, 1% HSA (Baxter Medical AB, Kista, Sweden),
0.1 mg/mL cephalotin (Eli Lilly, Indianapolis, IN), pH
adjusted to 7.4. Medium was then removed and centri-
fuged for 5 min at 450 g. Aliquots of medium were
stored at –80°C until analysis.
To evaluate the influence of albumin preparation, ex-
ploratory incubations for 2, 4, 6, 8, and 24 h were carried
out in medium lacking albumin and in medium supple-
mented with 1% HSA, 1% BSA Fraction V, or 1% BSA Es-
sentially Fatty Acid Free (Sigma-Aldrich, St Louis, MO).
The influence of 0.1% BSA was also studied. For prac-
tical reasons, only one tube of tissue was incubated with
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itional 20 h incubation, the second portion of incubation
medium was removed.
All incubations were performed at 37°C in a 5% CO2
atmosphere in an incubator (Steri-cycle CO2 Incubator,
Thermo Fischer Scientific, Marietta, OH); the medium
was stirred gently with a rotator.
Adipokine release
A multiplex immunoassay was used to measure the levels
of nine cytokines in the incubation medium: granulocyte-
macrophage colony-stimulating factor (GM-CSF), interferon-
γ (IFN-γ), IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, and
TNF-α (Human Pro-Inflammatory 9-Plex Ultra-Sensitive
Kit, Meso Scale Discovery, Gaithersburg, MD). ELISA was
used to measure adiponectin (Human adiponectin ELISA
kit, Millipore, Billerica, MA), chemerin (Human chemerin
ELISA kit, Millipore), omentin (Human omentin-1 ELISA,
Millipore), IL-6 (Quantikine High Sensitivity Human IL-6
ELISA, R&D Systems, Minneapolis, MN), and DPP4
(Quantikine Human DPPIV/CD26 ELISA kit, R&D Sys-
tems). Adipokine concentrations were expressed per g adi-
pose tissue.
Adipocyte size
About 500 mg of each fresh biopsy was digested with
collagenase [23], and the mean adipocyte diameter was
determined by computerized image analysis [24] with
Leica software (Leica QWin V3; Leica Microsystems,
Wetzlar, Germany). The cell suspension was placed be-
tween a siliconized glass slide and a cover slip and trans-
ferred to the microscope (X5 objective, DM6000B, Leica
Microsystems). Twelve random visual fields were photo-
graphed with a CCD-camera (DFC320, Leica Microsys-
tems). Uniform microspheres, 98 μm in diameter (Dynal,
Invitrogen Corporation, Oslo, Norway), served as refer-
ence. Mean adipocyte volume was calculated with the
Goldrick formula [25].
Immunohistochemistry
Paired subcutaneous and visceral adipose tissue speci-
mens were fixed in phosphate-buffered formalin, dehy-
drated, embedded in paraffin and sectioned at 4 μm.
After hydration and heat-induced antigen retrieval, a
monoclonal antibody targeted at human CD68 was
added to detect macrophages (Anti-Human CD68 clone
PG-M1, DakoCytomation, Denmark). MACH 3 Mouse
AP-Polymer and Warp Red was used as secondary and
detection reagents (Biocare Medical Concord, CA). The
sections were counter stained with hematoxylin and
mounted. Slides were digitalized (Mirax Desk Digital
Slide Scanner, Zeiss, Göttingen, Germany) and macro-
phages were counted and normalized for analyzedsection area (Mirax Viewer, Zeiss). Origin of the tissue
was unknown to the observer.
Endotoxin in incubation media
The endotoxin concentrations in unconditioned medium
with or without 1% of the different albumin preparations
were analyzed at the Laboratory of Clinical Bacteriology,
Sahlgrenska University Hospital, using a LAL assay with
quantitative chromogenic end point (Limulus Amebo-
cyte Lysate Endosafe Endochrome-K, Charles River
Endosafe, Charleston, SC). The lower limit of detection
was 0.5 pg/mL. All determinations were performed at
least in duplicate.
Statistical analysis
Values are expressed as mean ± SEM. To stabilize vari-
ances, values were logarithm-transformed. The influence
of different albumin preparations (1%) on adipokine re-
lease over time was determined by three-way analysis of
variance (medium, time, subject) followed by paired t
test and Bonferroni correction. The influence of 0.1%
BSA was evaluated by two-way analysis of variance
(medium, subject) followed by Dunnett’s test. Differ-
ences in adipokine release from subcutaneous and vis-
ceral adipose tissue over time were assessed by three-
way analysis of variance (depot, time, subject). To assess
differences in adiponectin release between obese and
nonobese subjects, we designed a split-plot experiment
with subjects as main plots and times as subplots. Differ-
ences between groups were estimated from main plots,
and differences between times were estimated from sub-
plots [26]. Adipocyte size and macrophage density in
subcutaneous and visceral adipose tissue was compared
by paired t test. The relationship between adiponectin
release and adipocyte size was investigated with Pearson
correlation analysis. Simple regression was used to inves-
tigate the relationship between IL-6 concentrations in
the medium determined by multiplex immunoassay and
ELISA (non-transformed data). P < 0.05 was considered
significant. All statistical analyses were conducted in
SPSS (v18, SPSS, Chicago, IL).
Results
Effects of BSA and HSA on cytokine and adiponectin
release from human adipose tissue
In three experiments, subcutaneous adipose tissue was in-
cubated for 2, 4, 6, 8, and 24 h in albumin-free medium or
medium supplemented with 1% HSA, 1% BSA Fraction V,
or 1% BSA Essentially Fatty Acid Free. Both preparations
of BSA markedly induced the release of all nine cytokines
as analyzed by multiplex immunoassay (Figure 1). Release
of all nine cytokines over 24 h was higher in the two
media containing BSA than in albumin-free medium or
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Figure 1 Effects of BSA and HSA on cytokine release from human adipose tissue. Adipose tissue was incubated for 2, 4, 6, 8, and 24 h in
albumin-free medium (blue) and medium supplemented with 1% HSA (red), 1% BSA Fraction V (purple), or 1% BSA Essentially Fatty Acid Free (black).
Concentrations of nine cytokines in the conditioned media were analyzed with a multiplex immunoassay; (A) granulocyte-macrophage colony-
stimulating factor (B) interferon-γ (C) IL-1β (D) IL-2 (E) IL-6 (F) IL-8 (G) IL-10 (H) IL-12p70 (I) TNF-α. Insets show detailed plots of cytokine release in
medium without albumin and in medium with HSA. Concentrations are ng/mL/g adipose tissue for IL-6 and IL-8 and pg/mL/g adipose tissue for the
remaining cytokines. Values mean ± SEM (n = 3). Both media containing BSA markedly induced the release of all nine cytokines vs albumin-free
medium or medium containing HSA over 24 h (p < 0.001). The two BSA preparations had similar effects, as did HSA and no albumin.
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containing BSA than in medium containing HSA. TNF-
α release at 24 h was 37-fold greater after incubation
with BSA Fraction V and 47-fold greater after incubation
with BSA Essentially Fatty Acid Free than after incuba-
tion with HSA. Cytokine concentrations did not differ
between the two media containing BSA (Figure 1) orbetween albumin-free medium and medium containing
HSA (Figure 1, insets). The adiponectin concentration in
the medium was not influenced by albumin supplemen-
tation, as analyzed by specific ELISA (data not shown).
Medium supplemented with 0.1% BSA Fraction V and
0.1% BSA Essentially Fatty Acid Free also induced cyto-
kine release. After 4 h, concentrations of all cytokines,
Svensson et al. BMC Endocrine Disorders 2014, 14:7 Page 5 of 10
http://www.biomedcentral.com/1472-6823/14/7except IL-2 and IL-6, were higher in both media with
0.1% BSA than in albumin-free medium (p < 0.05), as an-
alyzed by multiplex immunoassay. After additional 20 h
of incubation, concentrations of all nine cytokines were
higher in both media with 0.1% BSA than in albumin-
free medium (p < 0.05 IFN-γ, p < 0.001 all other cyto-
kines) (data not shown).Endotoxin concentration in incubation media
The endotoxin concentration in a batch of unconditioned
medium without albumin was <0.5 and 1.6 pg/mL (dupli-
cate). In three batches of unconditioned medium supple-
mented with 1% HSA, the endotoxin concentration was
6.2, 9.1, and 3.8 pg/mL, respectively. The corresponding
concentrations of endotoxin in medium containing 1%
BSA Fraction V and 1% BSA Essentially Fatty Acid Free
were 9200 and 11800 pg/mL.Adipocyte size in subcutaneous and visceral human
adipose tissue
Adipocyte size in 11 paired biopsies of subcutaneous
and visceral adipose tissue was analyzed with a comput-
erized technique. The mean adipocyte volume was simi-
lar in subcutaneous and visceral adipose tissue (730 ±
160 vs 665 ± 217 pL, p = 0.153). The mean diameter of
reference microspheres was 97.63 ± 0.25 μm (range
97.21–97.90 μm, n = 11). On average, 601 subcutaneous
adipocytes (range 322–1245) and 515 visceral adipocytes
(range 232–1164) were analyzed in each biopsy.Macrophage density in subcutaneous and visceral human
adipose tissue
The density of macrophages in 11 paired biopsies of sub-
cutaneous and visceral adipose tissue was analyzed using
immunohistochemistry. Macrophage density was higherFigure 2 CD68 immunoreactivity of human adipose tissue. Positive sig
Arrows indicate macrophages. Paired biopsies of (A) subcutaneous and (B)in visceral than subcutaneous adipose tissue (1.74 ± 0.61
vs 0.39 ± 0.14 macrophages/mm2, p < 0.05) (Figure 2).
Evaluation of the final short-term incubation protocol
including HSA
Subcutaneous adipose tissue from 10 subjects (five obese
and five nonobese) was incubated for 2, 4, 6, 8, and 24 h
in medium containing 1% HSA according to our final in-
cubation protocol. Eleven paired biopsies of subcutane-
ous and visceral adipose tissue was also incubated
accordingly. Adiponectin and omentin concentrations in
the media were analyzed by ELISA. As expected, adipo-
nectin was more abundantly released from adipose tissue
of nonobese than of obese subjects (p < 0.05) (Figure 3A),
and adiponectin release from subcutaneous adipose
tissue was inversely associated with subcutaneous adipo-
cyte size at 4 h (r = −0.85, p < 0.05, n = 7) and 24 h (r =
−0.84, p < 0.05, n = 7). As expected, omentin was almost
exclusively released from the visceral depot (p < 0.001)
(Figure 3B).
Release of cytokines from subcutaneous and visceral
adipose tissue
Eleven paired biopsies of subcutaneous and visceral adi-
pose tissue was incubated according to our final protocol.
As shown by multiplex immunoassay, release of all nine
cytokines but IL-6 were more abundant from visceral than
subcutaneous adipose tissue over 24 h of incubation (GM-
CSF p < 0.001, INF-γ p < 0.001, IL-1β p < 0.001, IL-2 p <
0.01, IL-6 p = 0.062, IL-8 p < 0.001, IL-10 p < 0.01, IL-
12p70 p < 0.001, TNF-α p < 0.001) (data not shown).
Release of adiponectin, chemerin, IL-6, and DPP4 from
subcutaneous and visceral adipose tissue
Paired biopsies of subcutaneous and visceral adipose tis-
sue were incubated according to our final protocol, andnal appears red. Sections were counterstained with hematoxylin.






























































Figure 3 Release of adiponectin and omentin from human adipose tissue. Evaluation of the final incubation protocol including HSA.
(A) Subcutaneous adipose tissue (SAT) from 10 subjects (5 obese and 5 nonobese) and (B) 11 paired biopsies of subcutaneous and visceral
adipose tissue (VAT) were incubated for 2, 4, 6, 8, and 24 h in medium containing 1% HSA according to our final incubation protocol. The media
were analyzed for (A) adiponectin and (B) omentin by ELISA. As expected, adiponectin was more abundantly released from adipose tissue of
nonobese than obese subjects (p < 0.05) (A), and omentin was almost exclusively released from the visceral depot (p < 0.001) (B).
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were determined by ELISA. Adiponectin was more abun-
dantly released from subcutaneous than visceral adipose
tissue (p < 0.01, n = 7) (Figure 4A). IL-6 release from the
depots was similar (p = 0.315, n = 11) (Figure 4B), while
chemerin and DPP4 were more abundantly released from
























































Figure 4 Release of adiponectin, IL-6, chemerin, and DPP4 from subc
Concentrations of adiponectin, IL-6, chemerin and DPP4 in media from pai
medium containing 1% HSA according to our final protocol were determin
subcutaneous than visceral adipose tissue (p < 0.01, n = 7) (A). IL-6 release
(C) and DPP4 (D) were more abundantly released from visceral adipose tisn = 11) (Figure 4C and 4D). Adipokine release was linear
for a maximum of 2–6 h.
Medium IL-6 concentrations determined by multiplex
immunoassay and ELISA
The IL-6 concentration in 148 samples of medium were















































utaneous adipose tissue (SAT) and visceral adipose tissue (VAT).
red biopsies of subcutaneous and visceral adipose tissue incubated in
ed by ELISA. Adiponectin was more abundantly released from
from the depots was similar (p = 0.315, n = 11) (B), while chemerin
sue (p < 0.05 and p < 0.001, respectively, n = 11).
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(y = 0.714x, R = 0.987, p < 0.001), indicating almost com-
plete agreement between the methods while the multiplex
technique systematically underestimated the IL-6 concen-
tration in the samples by about 30%.
Discussion
This study shows that adiponectin, chemerin, eight pro-
inflammatory cytokines, and DPP4, all inflammatory
and/or metabolic biomarkers, are released from human
adipose tissue in a depot-dependent manner. Chemerin,
cytokines, and DPP4 were more abundantly released
from visceral than subcutaneous adipose tissue, while
adiponectin release was higher from the subcutaneous
depot. Our findings also showed that cytokine release
from human adipose tissue was markedly induced by
BSA but not by HSA which was therefore used in our
final protocol.
In particular, when comparing adipose tissue biopsies—
from different groups of subjects, from different depots,
or from an individual at different time points—with re-
spect to adipokine/cytokine release, in vitro conditions
must be standardized and selected with care [18]. In tests
of our system, we found that HSA added to the medium,
in contrast to BSA, did not induce cytokine release from
human adipose tissue [20]. Using our final incubation
protocol to monitor adipokine release over 24 h, we also
obtained results consistent with previous well-established
clinical findings [27-31]. First, adiponectin release was
higher from abdominal biopsies of nonobese subjects than
obese subjects [27,28,31]. Second, adiponectin release
from subcutaneous adipose tissue was inversely associated
with adipocyte size [29,30]. Further, omentin was released
almost exclusively from visceral AT, consistent with re-
ports that omentin mRNA is barely detectable in human
subcutaneous adipose tissue or markedly lower in the sub-
cutaneous than in the visceral depot [32,33]. Taken to-
gether, these findings suggest that our in vitro system is
suitable for assessing the adipose tissue secretome and for
investigating relative differences in adipokine/cytokine re-
lease from adipose tissue depots.
It may be noted that no differences in cytokine release
was observed between medium containing HSA and
medium without albumin. In a short-term incubation
system like ours, with a high medium-to-adipose tissue
ratio, supplementation of the medium with albumin may
not be necessary.
As in a previous study of isolated adipocytes [20], cyto-
kines were massively released when adipose tissue pieces
were incubated in the presence of 0.1% or 1% BSA. Our
results suggest that this effect of BSA may be mediated by
a high concentration of endotoxin although immunomod-
ulatory effects of albumin, not due to endotoxin contam-
ination, also has been reported [34]. Depending on thecell/tissue type, endotoxin has a variety of effects mediated
at the transcriptional and/or translational level. At low
concentrations, the endotoxin lipopolysaccharide (LPS)
reportedly increases the expression and release of cyto-
kines from monocytes, monocyte-derived macrophages
and in vitro differentiated adipocytes [35-37]. Levels of IL-
8 mRNA in human mononuclear cells, cultured for 10
days for differentiation, were increased after a 4-h expos-
ure to LPS at a concentration of 1 pg/mL [35]. However,
relatively slow IL-8 protein secretion from the same cells
was reported only after stimulation with 10 ng/mL LPS,
making it difficult to draw conclusion about the LPS dose
required for an effect on IL-8 release in this type of
macrophage [35]. In our study, the endotoxin level was
about 1 pg/mL in albumin-free medium and 3–10 pg/mL
in incubation medium containing 1% HSA. Analysis of
our conditioned media over 24 h revealed no differences
in cytokine concentrations between media with or without
HSA, despite the somewhat higher endotoxin level in
medium containing HSA. This finding strongly suggests
an absent or negligible effect of endotoxin, or other poten-
tial immunomodulatory feature of albumin, in our incuba-
tion system.
As mentioned above, measures of obesity are associated
with reduced plasma levels of adiponectin, an adipokine
predominantly produced by adipocytes [27,28,31,38]. Ac-
cumulation of visceral and truncal fat, in particular, may
be linked to hypoadiponectinemia [28,39]. However,
in vitro studies of adiponectin release from human sub-
cutaneous and visceral adipose tissue have yielded incon-
sistent results. Adiponectin release from the depots was
similar after incubation of tissue pieces for a couple of
hours or for two days [40,41], while secretion of adiponec-
tin was 28% higher from omental than subcutaneous adi-
pocytes in primary culture, although the difference did
not reach statistical significance [42]. In primary cultures
of adipocytes from women with visceral obesity, adiponec-
tin release was lower in omental than subcutaneous adipo-
cytes [43]. Considerable methodological differences may
underlie these discrepancies. Consistent with our findings,
gene expression studies showed lower adiponectin mRNA
levels in visceral than in subcutaneous adipose tissue in
both lean and obese subjects [44,45].
To our knowledge, the possibility that release of che-
merin is depot-dependent has not been investigated by
incubation of human adipose tissue. Chemerin is a ra-
ther novel adipokine that regulates adipogenesis and
may induce insulin resistance [46,47]. In obese subjects,
elevated circulating levels correlate with BMI and mea-
sures of central adiposity, such as waist-hip ratio, waist
circumference, and visceral adipose tissue mass [48].
Further, expression of chemerin mRNA in adipose tissue
of patients with type 2 diabetes was more pronounced in
the omentum than in the subcutaneous depot, suggesting
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[49]. In the present study, the higher chemerin release
from the visceral than the subcutaneous depot was mar-
ginal but still significant over 24 h.
DPP4, another recently discovered adipokine, may also
impair insulin sensitivity [50]. Serum DPP4 is increased
in obesity and reduced after weight loss and is a poten-
tial biomarker of metabolic syndrome [50]. In contrast,
expression of DPP4 mRNA in subcutaneous adipose tis-
sue was higher in lean women than in age-matched
obese women [51]. In the present study, the first to in-
vestigate potential depot-dependent release of DPP4
from adipose tissue, visceral adipose tissue was by far
the major site. This finding is consistent with a western
blot analysis that showed higher DPP4 levels in visceral
than in subcutaneous adipose tissue in obese subjects,
and a similar trend also in lean subjects [50].
Accumulating evidence suggests that obesity—in par-
ticular central/visceral accumulation of fat—and its co-
morbidities correlate with increases in circulating levels
of inflammatory proteins such as C-reactive protein and
IL-6 [4,5,52,53]. Plasma IL-6 concentrations were also
reported to be higher in portal vein than in peripheral
artery blood in obese subjects suggesting that visceral fat
is an important source of IL-6 in obese people [54]. In
vitro studies comparing release of proinflammatory cyto-
kines such as IL-1β, IL-6, IL-8, and IL-18 from subcuta-
neous and visceral adipose tissue, usually in presence of
BSA or fetal calf serum [13,15,53,55] but also in serum/
albumin-free medium [13], generally show that the vis-
ceral depot is by far the dominant site [13,15,55,56],
consistent with our findings. However, for TNF-α, similar
release in the depots was previously reported [56,57]. Fur-
ther, nonfat cells of the tissue are thought to be respon-
sible for the major part of cytokine release [13,15,55], in
line with our observation of higher macrophage density in
the visceral depot. A larger number of observations would
probably be required to demonstrate a significant associ-
ation between macrophage density and cytokine release
although we observed positive relationships (not shown).
We found that release of IL-6, unlike the other cytokines
we studied, was similar in the subcutaneous and visceral
depots, although it tended to be higher in visceral adipose
tissue. The reason for this is not clear but in light of previ-
ous clinical observations, and the fact that all other
investigated cytokines in the present study were more
abundantly released from the visceral depot, it is reason-
able to assume that the non-significant difference between
the depots regarding IL-6 release is due to the relatively
small number of observations which limited our power.
Another possible limitation of this study is the rather
heterogeneous group of patients included. However, ana-
lysis of paired biopsies from the obese subjects separ-
ately did not affect the results obtained. Further, themultiplex immunoassay is mainly intended for screening
purposes. However, we observed an almost complete
agreement between the multiplex immunoassay and the
specific ELISA regarding analysis of IL-6 although the
multiplex technique systematically underestimated the IL-
6 concentration by about one third.
Conclusions
Taken together, our findings show that human adipose
tissue is characterized by depot-dependent release of
many adipokines. Chemerin, GM-CSF, IFN-γ, IL-1β, IL-
2, IL-8, IL-10, IL-12p70, TNF-α, and DPP4 were more
abundantly released from visceral than subcutaneous
adipose tissue, while adiponectin release was higher
from the subcutaneous depot. These results highlight
functional differences between visceral and subcutaneous
adipose tissue, and a mechanistic link between regional fat
accumulation and metabolic disorders. Our results also
demonstrate that the system applied, including HSA in-
stead of BSA, is suitable for further investigations of the
human adipose tissue secretome and relative differences
between depots. Further, for any in vitro system for hu-
man adipose tissue or adipocytes, potential albumin ef-
fects on tissue/cell function should be considered.
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